Sirtris Pharmaceuticals to Present at the 15th Annual Emerald Asset Management Investment Forum February 7
January 31 2008 - 8:06AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that it will be presenting at the Emerald Asset Management
Fifteenth Annual Groundhog Day Investment Forum on Thursday,
February 7th, 2008 at 9:00 am EST. Sirtris recently announced
positive Phase 1b clinical trial results with drug candidate
SRT501, a proprietary formulation of resveratrol, in patients with
Type 2 Diabetes. SRT501, which targets the SIRT1 enzyme, was found
to be safe and well-tolerated, and significantly lowered glucose in
an oral glucose tolerance test conducted as part of the 28 day
Phase 1b trial. Sirtris has new chemical entities (NCEs), which
activate SIRT1, that are chemically distinct from resveratrol and
are 1000 times more potent. The company plans to have one of these
NCEs in clinical trials in the first half of 2008. Sirtris will
discuss the company's strategy for discovering and developing
first-in-class therapeutics that modulate sirtuins, a class of
enzymes associated with age-related diseases, as well as the
company's clinical progress. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators for diseases of aging, the progress and results
of pre-clinical and clinical studies of SIRT1 activators,
development of first-in-class therapeutics that modulate sirtuins,
and the potential of sirtuin modulators to receive regulatory
approval. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company's product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the Company to gain market acceptance of the Company's
product candidates, and those other risks factors that can be found
in the Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024